<DOC>
	<DOCNO>NCT00925769</DOCNO>
	<brief_summary>This 2 part study evaluate safety efficacy combination Avastin , Tarceva Xeloda ( ATX ) second-line treatment patient locally advance and/or metastatic pancreatic cancer . In first part study , cohorts patient receive escalate dos combination treatment determine maximum tolerate dose . The recommended dose use second part study determine efficacy ATX regime , term effect disease progression . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>ATX Study : A Study Avastin ( Bevacizumab ) , Tarceva ( Erlotinib ) Xeloda ( Capecitabine ) Patients With Locally Advanced and/or Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; pancreatic cancer locally advance and/or metastatic disease ( stage IV ) ; chemonaive metastatic locally advanced disease ; ECOG performance status 02. local ( stage IA IIB ) locally advanced ( stage III ) pancreatic cancer ; previous exposure Avastin , Tarceva Xeloda ; primary tumor within last 5 year prior enrollment , except adequately treated cancer situ cervix , basal cell skin cancer ; current recent chronic use aspirin ( &gt; 325 mg/day ) full therapeutic dose anticoagulant thrombolytic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>